MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

20 April 2015

Melanoma Institute Australia and its key affiliate, Crown Princess Mary Cancer Centre Westmead were the highest recruiting centre worldwide for the study into the immunotherapies pembrolizumab versus ipilimumab, in advanced melanoma, with the findings published in the New England Journal of Medicine, the leading medical journal in the world.

The study found that the anti–PD-1 antibody pembrolizumab (trade name KEYTRUDA®) prolonged survival, and had less high-grade toxicity, compared with ipilimumab (trade name YERVOY®) in patients with advanced melanoma, that is, melanoma that has spread to distant parts of the body.

Associate Professor Georgina Long from Melanoma Institute Australia and University of Sydney said, “Here at MIA and Westmead we have been undertaking clinical trials with immunotherapy treatment using anti-PD-1 drugs for over three years, and these findings are the final piece of data that show the anti–PD-1 antibody pembrolizumab is better than current treatments for patients with advanced melanoma.”

The immune checkpoint inhibitor, ipilimumab, is one of the standard treatments for patients with advanced melanoma. The latest findings show that pembrolizumab, which inhibits the programmed death receptor 1 (PD-1) immune checkpoint on immune T cells, has antitumor activity: that is, it reduces the size of the tumours in patients with advanced melanoma in approximately 70% of patients, with deep reduction in over 30%, and prolongs survival compared with ipilimumab.

This clinical trial using pembrolizumab (KEYTRUDA®) recorded a 1 year survival rate of 74%, whilst those who received ipilimumab (YERVOY®) had a 1 year survival rate of 58%. Five years ago, only 30-35% of patients with advanced melanoma survived 1-year.

“These results are world-first, where two effective immunotherapies are directly compared, and we significantly improve outcomes for patients even further. This is great news for Australia, which has the highest incidence of melanoma in the world, and an Australian dies from this disease every 6 hours” said Assoc Prof Georgina Long. “This is evidence which will be considered by bodies around the world, including the Australian Government, to make these drugs accessible to all melanoma patients".

Research Co-Director of Melanoma Institute Australia and Macquarie University Professor Rick Kefford claims, “this breakthrough is probably the most important development in the treatment of this disease ever, and a landmark in terms of cancer treatment in general.”

Others Australian centres involved in this trial include: Newcastle Melanoma Unit, NSW; The Austin Hospital, VIC; Sir Charles Gardiner Hospital, WA; Princes Alexandra Hospital, QLD; Sydney Cancer Centre, RPAH, NSW.

 

Danny's inspiring survival story
26 May 2020

Danny's inspiring survival story

“I had a complete response within about six months. All of my tumours disappeared."

Tags: melanoma
Professor Richard Scolyer achieves h-index of 100
26 May 2020

Professor Richard Scolyer achieves h-index of 100

MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.

How we connected at Melanoma March Virtual 2020
21 Apr 2020

See how we connected at Melanoma March Virtual 2020

We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.

Melanoma meets its match.
07 Apr 2020

Melanoma meets its match.

A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.  

 

Next Steps for National Screening Program for Melanoma
23 Mar 2020

Next Steps for National Screening Program for Melanoma

On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.

Melanoma March Update
13 Mar 2020

Melanoma March Update

Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.   

Saving lives this summer: 'Game On Mole!'
11 Mar 2020

Saving lives this summer: 'Game On Mole!'

Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.

PBS boost for melanoma patients
01 Mar 2020

PBS boost for melanoma patients

Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.

An open letter to all young Australians
25 Feb 2020

An open letter to all young Australians

Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.

MIA leads world-class skin tumour pathology conference
14 Feb 2020

MIA leads world-class skin tumour pathology conference

Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.

MAFS, it is time for a reality check on solariums.
07 Feb 2020

MAFS, it is time for a reality check on solariums.

It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.

Community Fundraising January Wrap-Up
07 Feb 2020

Community Fundraising January Wrap-Up

Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.

Kyly Clarke urges Aussies to step up to save lives from melanoma
03 Feb 2020

Kyly Clarke urges Aussies to step up to save lives from melanoma

Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.

Improving support for our patients across Australia.
03 Feb 2020

Improving support for our patients across Australia.

Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.   

Boost to melanoma support in WA
31 Jan 2020

Boost to melanoma support in WA

Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.

New Test to Predict Primary Melanoma Progression
21 Jan 2020

New Test to Predict Primary Melanoma Progression

Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.

Community Fundraising December Wrap-Up
14 Jan 2020

Community Fundraising December Wrap-Up

We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.

Two melanoma treatments approved for PBS listing
24 Dec 2019

Two melanoma treatments approved for PBS listing

Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.    

Immunotherapy: the decade's biggest health advance
23 Dec 2019

Immunotherapy: the decade's biggest health advance

An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.  

 

Boost to Melanoma Services in the Riverina
12 Dec 2019

Boost to Melanoma Services in the Riverina

Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.